In patients with AD, downregulation of glucose metabolism leads to decreased O-GlcNAcylation of tau, ultimately resulting in tau phosphorylation at the AD-related sites, suggesting this glycan has a neuroprotective role [103]. Here, MAPT is linked to Alzheimer disease.